Pacira BioSciences Stock (NASDAQ:PCRX), Analyst Ratings, Price Targets, Predictions

The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by HC Wainwright & Co. on May 8, 2024. The analyst firm set a price target for $57.00 expecting PCRX to rise to within 12 months (a possible 92.93% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacira BioSciences (NASDAQ: PCRX) was provided by HC Wainwright & Co., and Pacira BioSciences reiterated their buy rating.

The last upgrade for Pacira BioSciences Inc happened on August 3, 2023 when TD Cowen raised their price target to $50. TD Cowen previously had a market perform for Pacira BioSciences Inc.

There is no last downgrade for Pacira BioSciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a reiterated with a price target of $0.00 to $57.00. The current price Pacira BioSciences (PCRX) is trading at is $29.55, which is within the analyst’s predicted range.